Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis.
暂无分享,去创建一个
[1] I. Tannock,et al. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial , 2002, The Lancet.
[2] B N Bundy,et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Joos Vandewalle,et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma , 2001, The Lancet.
[4] H. V. van Houwelingen,et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] E. Atkinson,et al. Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Piccart,et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. , 2000, Journal of the National Cancer Institute.
[7] V. Abeler,et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument , 2000, International Journal of Gynecologic Cancer.
[8] D. Alberts,et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. , 1998, British Journal of Cancer.
[9] D. Gershenson,et al. Ovarian Cancer: Controversies in Management , 1997 .
[10] M. Piccart,et al. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview. , 1997, European journal of cancer.
[11] W. Gregory,et al. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] P. Reimer,et al. [High dose chemotherapy with autologous stem cell transplantation]. , 1997, Fortschritte der Medizin.
[13] D. Alberts,et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. , 1996, The New England journal of medicine.
[14] G. Viale,et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] D. Cruickshank,et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] G. Fleuren,et al. DNA index reflects the biological behavior of ovarian carcinoma stage I-IIa. , 1996, Gynecologic Oncology.
[17] E. Partridge,et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, The New England journal of medicine.
[18] H. Earl,et al. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. , 1995, British Journal of Cancer.
[19] M. Gore,et al. The importance of dose and schedule in cancer chemotherapy: epithelial ovarian cancer , 1995, Anti-cancer drugs.
[20] M. Bissery,et al. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. , 1995, Anti-cancer drugs.
[21] M. Buyse,et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. , 1995, The New England journal of medicine.
[22] J. Thigpen,et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] C. Gillis,et al. Management of ovarian cancer: referral to a multidisciplinary team matters. , 1994, British Journal of Cancer.
[24] F. Ognibene,et al. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. , 1994, Journal of the National Cancer Institute.
[25] M. Christian,et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] V. Abeler,et al. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. , 1993, American journal of obstetrics and gynecology.
[27] K. Nielsen,et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). , 1993, Gynecologic oncology.
[28] C. Runowicz,et al. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] S. Rubin,et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. , 1992, Gynecologic oncology.
[30] E Wiltshaw,et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] D. Ettinger,et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. , 1989 .
[32] E. Yordan,et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study , 1986, Cancer.
[33] T. Lister,et al. Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Y. Ostchega,et al. High dose cisplatin and high dose carboplatin in refractory ovarian cancer. , 1985, Cancer treatment reviews.
[35] P. Vasey. Survival and longer-term toxicity results of the SCOTROC study : docetaxel-carboplatin (DC) vs. paclitaxelcarboplatin (PC) in epithelial ovarian cancer (EOC) (abstract) , 2002 .
[36] E. Eisenhauer,et al. First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin (TEC) vs paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-NCIC CTG Gynaecological Cancer Intergroup phase III trial , 2002 .
[37] Taylor Murray,et al. Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.
[38] M. Parmar,et al. Results of a randomized trial in 923 patients with high-risk early ovarian cancer, comparing adjuvant chemotherapy with no further treatment following surgery , 2001 .
[39] F M Muggia,et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] J. Neijt,et al. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care? , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[41] Allen Dg,et al. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. , 1995 .
[42] H. Ngan,et al. A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group. , 1989, Chemotherapy.